SAS Output

19-NOV-2017 6:10

BREAST ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9400 9383 663 264 90 0 0 02/28/2011 408 203
            9383 663 264 90 0 0      
 
    2 Y 2 Chemo and Endocrine Therapy 4000 2547 230 99 36 2 0 02/28/2011    
        3 Endocrine Therapy Alone   2536 232 100 38 2 0      
            5083 462 199 74 4 0      
 
  S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 1900 705 202 92 47 17 5 09/12/2013 452 235
        2 Blinded drug + Endocrine   711 213 103 57 13 2      
            1416 415 195 104 30 7      
 
  S1222-Brst,Fulv. +/- Ever. +/- Anastr. 1 T 1 Blinded treatment 840 12 0 0 0 0 0 05/15/2014 23 9
        2 Blinded treatment   12 0 0 0 0 0      
        3 Blinded treatment   13 0 0 0 0 0      
            37 0 0 0 0 0      
 
  S1416-Brst, TNBC/BRCA, Cis+/- ABT-888 1 Y 1 Blinded Drug + Cisplatin 333 85 80 45 24 5 1 09/15/2016 264 126
        2 Blinded Drug + Cisplatin   85 81 46 26 6 1      
            170 161 91 50 11 2      
 
  S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 1000 111 111 83 51 21 5 01/18/2017 389 175
            111 111 83 51 21 5      
 
    2 Y 2 Observation 1000 50 50 43 26 13 2 01/18/2017    
        3 MK-3475 (Pembrolizumab)   44 44 33 17 5 3      
            94 94 76 43 18 5      
 
Yes A011106-Breast, Neoadj, ALTERNATE study 1 E Total Registrations   51 23 14 8 1 0 04/29/2014 247 116
            51 23 14 8 1 0      
 
  E1Z11-Brst,Genetic Predictors of AIMSS 1 E Total Registrations   144 6 2 1 0 0 08/13/2013 227 81
            144 6 2 1 0 0      
 
No A011202-Breast, Nodal XRT +/- ALND 0 E Total Registrations   147 59 31 18 7 1 03/20/2014 347 182
            147 59 31 18 7 1      
 
    1 E Total Registrations   58 22 9 6 1 0 03/20/2014    
            58 22 9 6 1 0      
 
  A011401-Breast, adj, Stage II/III HER2-, weight loss 1 E Total Registrations   87 84 52 20 11 4 10/05/2016 425 229
            87 84 52 20 11 4      
 
    2 E Total Registrations   75 74 50 20 9 3 10/05/2016    
            75 74 50 20 9 3      
 
  A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 1 E Total Registrations   21 21 19 10 3 1 03/20/2017   197
            21 21 19 10 3 1      
 
  A221405-Breast, ET interruption, Pregnancy Outcomes 1 E Total Registrations   6 6 5 4 3 1 05/08/2017   58
            6 6 5 4 3 1      
 
  B51-Breast, Regional Nodal XRT 1 E Total Registrations   23 15 11 6 3 0 06/13/2014 422 218
            23 15 11 6 3 0      
 
  B55-Brst, Adj Olaparib for BRCA,TNBC 1 E Total Registrations   46 19 7 5 1 0 12/15/2014 408 180
            46 19 7 5 1 0      
 
    2 E Total Registrations   21 11 6 3 2 0 12/15/2014    
            21 11 6 3 2 0      
 
  E2112-Brst,Adv,Exemestane+/-Entinostat 1 E Total Registrations   42 18 10 4 2 1 04/01/2015 285 167
            42 18 10 4 2 1      
 
  EA1131-Brst, TNBC, Post-op Chemo vs Obs 0 E Total Registrations   14 9 5 2 0 0 11/12/2015 298 123
            14 9 5 2 0 0      
 
    1 P Total Registrations   7 6 6 2 0 0 11/12/2015    
            7 6 6 2 0 0      
 
  NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA 1 E Total Registrations   1 1 1 1 0 0 09/22/2017   4
            1 1 1 1 0 0      
 
  NRGBR003-Brst,Adj,TNBC,AC -> WP +/- Carbo 1 E Total Registrations   46 23 14 7 3 1 10/16/2015 447 229
            46 23 14 7 3 1